There is growing evidence of a link between ED, metabolic syndrome (MS) and cardiovascular disease (CVD). The study was to explore the prevalence of MS using three different definitions (World Health Organization (WHO), International Diabetes Foundation (IDF) and Adult Treatment Panel III (ATP III)), and to compare the association of CVD in ED outpatients using these definitions. This study enrolled 254 participants with a mean age of 55.3±0.9 years (range, 21 to 81 years) with ED as diagnosed by International Index of Erectile Function score. All participants underwent MS evaluation based on the three criteria. Differences of MS prevalence, demographical characteristics, biochemical profiles, pro-inflammatory and inflammatory markers, echocardiographic characteristics and the association with Framingham cardiac risk score (FCRS) were compared. The presence of diabetes mellitus (DM) in the WHO group and high waist girth in the IDF group were significant because of the necessity of respective criteria. The MS prevalence in the WHO, IDF and ATP III groups was 30.7, 34.3 and 36.6%, respectively (P ¼ 0.367). The degrees of agreement among each definition were substantial to perfect. No significant findings in echocardiographic characteristics, biochemical, inflammatory and pro-inflammatory markers were noted. The FCRS showed borderline nonsignificant difference (17.9 ± 0.4, 16.8 ± 0.4 and 16.9 ± 0.4, P ¼ 0.079); however, the FCRS was more closely correlated with the WHO than with the IDF and ATP III (Spearman's correlation coefficients were 0.522, 0.531 and 0.462, respectively; P ¼ 0.021). In patients o 55 years of age and those who smoke, the Spearman's correlation in the WHO group was significantly higher than in the IDF and ATP III groups. The prevalence of the MS using different definitions in ED patients was not different. The WHO-defined MS was more closely associated with CVD.
Introduction
ED is a common problem and adversely affects the quality of life for men in middle and old age. The Massachusetts Male Aging study showed that 52% of men showed some degree of ED between subject ages 40 and 70 years. Besides, the prevalence of complete impotence tripled from 5 to 15% in this age bracket. 1 It is now well documented that many risk factors for coronary artery disease (CAD), such as hypertension, smoking, dyslipidemia, diabetes mellitus (DM) and lack of physical exercise, are also risk factors for ED. 2, 3 These shared risk factors contribute to endothelial dysfunction and impede the ability of the arteries to dilate, thereby inhibiting the occurrence of normal erection. In addition, a strong and independent correlation between ED and silent CAD had been reported in uncomplicated type 2 diabetic patients by Gazzaruso et al. 4 The authors found a higher ED prevalence in uncomplicated type 2 diabetic patients with, than those without, silent myocardial ischemia (33.8 vs 4.7%, P ¼ 0.000). Blumentals et al. 5 reported that men with ED had a twofold increase in risk for acute myocardial infarction after correcting for risk factors and medications. Our previous study results also showed independent determinants, including many traditional cardiovascular risk factors and markers of vascular wall and ventricular function, of CAD in ED outpatients. 6 In addition, metabolic syndrome (MS), which refers to the clustering of criteria such as DM or impaired glucose tolerance, hypertension, obesity, dyslipidemia and/or microabluminuria, is closely associated with cardiovascular morbidity and mortality. 7, 8 The relationship of ED and MS had been well established by several studies. In the study by Bansal et al., 9 MS was found to occur in 43% of an ED population, whereas in only 24% of a matched patient population. Our previous study showed that the presence of MS, the number of MS components and certain traditional cardiovascular risk factors, especially high low-density lipoprotein cholesterol level and hypertension, may influence the ED severity. 10 Therefore, accumulating evidence demonstrates that a strong association exists between MS and ED, although this needs to be confirmed through further larger epidemiological studies.
Although the relationship among cardiovascular risk factors, MS and ED had been established; many different criteria for MS exist, and which definition is suitable for ED patients to predict cardiovascular risk remained unclear. Thus, the aim of this study was to investigate the relationship of different MS definitions and cardiovascular risk in ED patients.
Methods
A total of 254 male outpatients with a clinical diagnosis of ED visiting our urology clinic volunteered to participate into this study. Informed consent was obtained from all patients, and the study protocol was approved by the local ethics committee. All the participants had been referred to the urology clinic with an initial diagnosis of functional ED. The urologists carried out a history and examination on all men regarding their ED. The determination of ED severity was confirmed using the International Index of Erectile Function score.
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Blood was drawn for routine biochemical analyses after an overnight fast, with the patients in a supine position. All blood samples were drawn at the same time of the day (between 0800 and 1000 hours). Standard blood tests including serum fasting glucose level, lipid profiles and inflammatory and proinflammatory markers were carried out. The blood samples were separated, and then frozen at À80 1C until further use for analysis. Blood pressure was measured by a standardized sphygmomanometer after at least 10 min of rest. Participants' weight and height were measured dressed in an examination gown without shoes. Waist circumference was measured at a point midway between the lowest rib and the iliac crest in the standing position. Hip circumference was measured in the standing position in the plane of both major femoral trochanters. Body mass index was calculated by dividing body weight in kilograms by height in meters (kg m À2 ). Waist-to-hip ratio was calculated by dividing the waist circumference by the hip circumference. Microalbuminuria was determined as previously reported. 12 The Framingham cardiac risk score (FCRS) was calculated using an algorithm taking into account gender, age, total cholesterol, highdensity lipoprotein (HDL) cholesterol, systolic blood pressure and smoking, as described previously. 14-16 However, subjects were considered to have central obesity by Asian criteria (waist circumference X90 cm). The MS prevalence was evaluated according to the standard criteria of these different MS definitions, which are detailed in Table 1 .
According to the WHO definition, for a person to be defined as having the MS, they must have DM, impaired fasting glucose, impaired glucose tolerance or insulin resistance plus any two of the following five factors: hypertension (blood pressure (BP) X140/ 90 mm Hg or receiving anti-hypertensive medication), hyperlipidemia (triglyceride level X150 mg dl À1 or receiving specific treatment for this lipid abnormality), low HDL cholesterol level (o 35 mg dl À1 or specific treatment), obesity (BMI430 kg m À2 or waistto-hip ratio40.9) and microalbuminuria (albumin/ creatinine ratio X30 mg g
À1
).
According to the IDF definition, for a person to be defined as having the MS, they must have central obesity plus any two of the following four factors: hyperlipidemia (triglyceride level 4150 mg dl À1 or receiving specific treatment for this lipid abnormality), low HDL cholesterol level (o40 mg dl À1 or specific treatment), hypertension (BPX130/85 mm Hg or receiving anti-hypertensive medication) and fasting hyperglycemia (glucose X100 mg dl À1 or previously diagnosed as type 2 DM).
According to the ATP III definition, for a person to be defined as having the MS, they must have three or more of following risk factors: obesity (waist circumference 490 cm), hyperlipidemia (triglyceride level X150 mg dl À1 or receiving specific treatment for this lipid abnormality), low HDL cholesterol level (o 40 mg dl À1 or specific treatment), hypertension (BP X130/85 mm Hg or receiving anti-hypertensive medication) and fasting hyperglycemia (glucose X110 mg dl À1 or previously diagnosed as type 2 DM).
All the patients were examined by a cardiologist, and their vascular properties were studied by pulse pressure and determination of the brachial/ankle pulse wave velocity, ratio of mitral inflow velocity to Erectile dysfunction, cardiac risk and metabolic syndrome S-T Chang et al early diastolic velocity in the annulus by tissue Doppler imaging, and intima-media thickness of the common carotid artery. All of these have been described in our previous study.
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Main outcome measures The differences of prevalence, demographical characteristics, biochemical profiles, pro-inflammatory and inflammatory markers, echocardiographic characteristics, and FCRSs among different MS definitions (WHO, IDF and ATP III) were determined. The Statistical Package for Social Sciences (SPSS) version 14.0 for Windows (SPSS, Chicago, IL, USA) was used for statistical analysis. The chi-square test was used to compare the following parameters: presence of DM, hypertension, or MS, current smoking status and distribution of dyslipidemia or obesity. The independent t-test was used to compare ages and the biochemical and hormonal profiles. The results were expressed as mean ± standard error. Spearman's correlation coefficients were applied to evaluate correlations among variables. The k statistics was used to determine the degree of agreement between two related variables, as described by previous study. 18 The Kruskal-Wallis non-parametric analysis and Cochran's Q statistics were applied to compare the difference of FCRS among the three study groups. P-values p0.05 were considered to be statistically significant; a P value between 0.05 and 0.1 was defined as trending towards significance.
Results
A total of 254 ED patients were enrolled with a mean age of 55.3±0.9 years (range, 21 to 81 years). The prevalence of MS and its distribution based on the three MS definitions are shown in the Figure 1 and Table 2 . The prevalence of MS defined by the WHO, IDF and ATP III criteria were 30.7, 34.3 and 36.6%, respectively (P ¼ 0.367). Of all subjects, 58.7% did not have MS by any definition; whereas 41.5% of the subjects were classified as having MS by at least one definition. The agreement degrees among each definition were substantial (WHO and IDF; WHO and ATP III) to perfect (IDF and ATP III).
The demographical characteristics of the participants are shown in Table 3 . No differences in all variables of baseline characteristics, except the presentation of DM and high waist girth, were noted among the three groups. However, these differences are mainly caused by the inclusion criteria requirement of each MS definition. No differences in biochemical testing, pro-inflammatory and inflammatory markers, echocardiographic characteristics and vascular properties were found between the three groups (Tables 4 and 5 ). Erectile dysfunction, cardiac risk and metabolic syndrome S-T Chang et al
The FCRSs distribution in different MS definitions is illustrated in Table 6 . FCRSs showed borderline nonsignificance among the three groups by Kruskal-Wallis statistical analysis (total points, 17.9 ± 0.4, 16.8 ± 0.4, and 16.9 ± 0.4, respectively, P ¼ 0.079; 10-year cardiac risk, 18.5±1.4%, 18.5± 1.3%, and 18.0±1.2%, respectively, P ¼ 0.074). However, the Spearman's correlation coefficients between the different MS definitions and FCRS were 0.552, 0.531 and 0.462 by Cochran's Q statistical analysis, respectively (P ¼ 0.021). In subjects o55 years of age, the correlation coefficients between FCRS and the three different MS definitions were all increased (0.608, 0.458 and 0.541, respectively, P ¼ 0.028). In contrast, in patients with X55 years of age, the correlation coefficients were all decreased in the three different MS definitions (0.482, 0.378 and 0.375, respectively, P ¼ 0.317). In patients who smoke, the Spearman's correlation coefficients increased in the WHO group, but decreased in IDF and ATP III groups.
Discussion
Accumulating evidence suggests that MS is linked to cardiovascular disease (CVD). 7, 8 In addition, previous studies have shown a connection among ED, MS and CVD, and the putative mechanism and pathophysiology are thought to be related to endothelial dysfunction. 10, [19] [20] [21] [22] Several reports have shown that the presence and severity of ED are associated with inflammatory markers and endothelial dysfunction. 23, 24 Similar pathogenic involvement of the nitric oxide (NO) pathway leading to the impairment of endothelium-dependent vasodilatation in the early phase, and obstructive vascular changes in the late phase, is shared by ED and other vascular diseases. 25, 26 Therefore, atherosclerosis characterized by vascular damage and NO-pathway impairment may partially explain the association between ED, MS and CVD.
Previous studies have reported a higher MS prevalence in ED patients, ranging from 34 to 43% (ref. 21, 22, 27) . In addition, Esposito et al. 22 illustrated that subjects with MS, in comparison with an age-and weight-matched control group, had an increased ED prevalence. However, the MS definitions used in these studies were not identical. Which MS definition is appropriate for correlation of CVD in ED patients had not been well investigated. In this cross-sectional study, the prevalence of Erectile dysfunction, cardiac risk and metabolic syndrome S-T Chang et al 1.7 ± 0.7 1.5 ± 0.6 1.4 ± 0.6 0.917 IL-6 (pg ml
97.9 ± 5.1 121. 12.6 ± 0. 106.4 ± 3.6 108.1 ± 3.0 107.7 ± 2.9 0.924
Abbreviations: baPWV, brachial/ankle pulse wave velocity; E/Et, ratio of mitral inflow E velocity to early diastolic velocity in the annulus derived by tissue Doppler imaging; IMT, intima-media thickness; MS, metabolic syndrome; LVM, left ventricular mass; LVMI, left ventricular mass index; PP, pulse pressure. 28 reported that, compared with the IDF definition, the ATP III definition was more closely correlated with high CVD prevalence. They found that the use of central obesity as a mandatory criterion by the IDF definition could result in the exclusion of subjects with X3 of the remaining 4 criteria who might also have an increased prevalence of CVD. Milionis et al. 29 reported that the odds ratio for ischemic stroke was 2.59 for ATP III-defined MS and 3.18 for National Heart, Lung and Blood Institute/American Heart Association (NHLBI/AHA)-defined MS. However, the association of IDF-defined MS with ischemic stroke was not significant. Luk et al. 30 reported that in patients with type 2 DM, the ATP III but not the IDF definition of MS, defined a subgroup of patients who had a higher risk of chronic kidney disease. In the Japan Diabetes Complication Study, which enrolled 1424 type 2 DM patients who were followed for 8 years for evidence of CAD and stroke, the IDF definition showed no improvement in the prediction of adverse CVD events in comparison with the ATP III and WHO definitions. 31 In contrast, Wei-ju et al. 32 showed that IDF-defined MS was more strongly associated with CAD than ATP IIIdefined MS. These data suggest that different definitions of MS correlate differently with CVD in different groups of patients. There are no identical standards for MS definitions to predict CVD risks agreed with each population group up to present. Therefore, it is important to derive an applicable MS definition in order to stratify potential cardiovascular risk for specific patient groups.
It is agreed that CVD deserves of more clinical attention and is the main clinical outcome of MS in general population, as well as in ED patients. Therefore, a complete and systematic evaluation should be taken in ED patients in order to identify those who require interventions and intensive treatments. To our best knowledge, there is lack of study focused on the use of MS definitions for ED patients, especially in association with FCRSs. In our study, the FCRS exhibited a borderline nonsignificant difference among the three groups by Kruskal-Wallis analysis. However, this trending toward a significant result implies that any two groups in the three different MS definition groups may have the difference existence. Cochran's Q statistical analysis for the MS groups indicated significant differences between the WHO vs ATP III group (P ¼ 0.021), WHO vs IDF group for subjects o 55 years of age (P ¼ 0.028) and WHO vs IDF group for subjects who smoke (P ¼ 0.039).
According to the results of this study, the WHO definition of MS for ED patients seems to be the most closely associated with CVD. The potential mechanism and reason that the WHO definition of MS was associated with high FCRS is unclear. However, glucose intolerance or DM is a required criterion of WHO-defined MS. Nevertheless, DM has long been recognized as a significant risk factor for CAD and has been acknowledged as a CAD equivalent. Therefore, this may be because the WHO definition addresses insulin resistance directly, unlike the ATP III criteria that is indirectly linked with insulin resistance and semi-obesity driven, and the IDF criteria that is focused on obesity. In our study, the presence of DM or glucose intolerance showed more closely associated with CVD than obesity for ED patients.
Limitations of this study
This study is limited by the sample size, and more participants are needed to amplify the difference between MS and FCRSs.
Conclusions
The primary goal to define MS for patients with ED was to stratify the potential hazard of CVD. In our study, the prevalence of the MS in ED patients was not different based on the definition of MS used. However, the relationship between MS and CVD was more pronounced using WHO definition of MS for this patient group. We suggest that WHO definition of MS may have significantly clinical usefulness and association with the CVD for ED patients.
